Drug Trial Radar · NCT05624112
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Nov 25, 2022
Primary completion
Jan 25, 2024
Study completion Jan 25, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 16-week, open label, exploratory study designed to investigate dupilumab's effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping. During the first 2 treatment weeks, patients will have 2 on-site visits/week, followed by one on-site visit/week up to Week 4, one on-site visit every two weeks from Week 4 to Week 8, and one on-site visit every 4 weeks up to Week 16 End of Treatment phase visit (EoT) thereafter. A follow-up visit by phone 4 weeks after the last study assessment at Week 16 will end the study for each participant (End of Study: EoS). The maximum duration of the study per participant will be 24 weeks.
Conditions
- Atopic Dermatitis
- Dermatitis Atopic
Interventions
DupilumabDrug
Dupilumab solution in a pre-filled syringe for Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in TEWL after 5 skin tape stripping (STS) assessed on lesional skin at Week16 in AD patients.Time frame: From baseline to week16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.